CLINICAL TRIALS PROFILE FOR MARIBAVIR
✉ Email this page to a colleague
All Clinical Trials for MARIBAVIR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002373 ↗ | The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients | Completed | Glaxo Wellcome | Phase 1 | 1969-12-31 | To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding. To obtain preliminary evidence of the in vivo anti CMV activity of different doses of 1263W94 in humans based on quantitative reduction of CMV load in semen and if possible in other biological fluids and to explore the dose response relationship in the anti-CMV activity of 1263W94. |
| NCT00223925 ↗ | Maribavir for Prevention of CMV After Stem Cell Transplants | Completed | Shire | Phase 2 | 2004-10-28 | Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants. |
| NCT00411645 ↗ | Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients | Completed | Shire | Phase 3 | 2006-12-13 | The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant. |
| NCT00497796 ↗ | Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients | Completed | Shire | Phase 3 | 2007-07-23 | The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant. |
| NCT01611974 ↗ | Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients | Completed | Shire | Phase 2 | 2012-07-17 | This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants. |
| NCT02775240 ↗ | Study of SHP620 (Maribavir) in Healthy Adults | Completed | Shire | Phase 1 | 2016-07-21 | The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MARIBAVIR
Condition Name
Clinical Trial Locations for MARIBAVIR
Trials by Country
Clinical Trial Progress for MARIBAVIR
Clinical Trial Phase
Clinical Trial Sponsors for MARIBAVIR
Sponsor Name
